FMP

FMP

Enter

CRTX - Cortexyme, Inc.

Financial Statements of Cortexyme, Inc.(CRTX), Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for

photo-url-https://financialmodelingprep.com/image-stock/CRTX.jpg

Cortexyme, Inc.

CRTX

NASDAQ

Inactive Equity

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

1.95 USD

0.05000007 (2.56%)

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep